
The annual Kennebunk Tour de Cure is a bike ride that’s part of a national effort by the American Diabetes Association. Riders must raise at least $200 to participate, though most go above and beyond that minimum, especially if they choose to form a team.
According to the Kennebunk Tour de Cure website, this year’s tour, the 25th annual, had 71 teams and 824 riders registered. They could choose from courses measuring 100 miles, 100 kilometers, 50 kilometers, 25 kilometers and 5 kilometers.
Patricia Belden, development manager at the American Diabetes Association and organizer of the Kennebunk Tour, said this year was a huge success both in terms of money raised and participants.
“This year, we have the most riders we’ve ever had,” said Belden. “We also have raised the most money that we’ve ever raised; it’s approaching $400,000. So we’re really excited.”
Monique Cole rode with a team representing RSM, a tax and accounting firm for which Cole works. She said the firm has a foundation that donates the minimum fundraising amount for all its employees who want to participate. Employees can then go above and beyond if they want.
This was Cole’s first year participating in the ride portion of the tour due to scheduling conflicts, though she said she’s helped with other aspects of the fundraiser before. On Sunday, she rode the 5K course with her son, as they share the same motiva- tion.
“We have some family friends with Type 1 diabetes, so it seemed like the appropriate thing to do,” Cole said.
Fellow 5K course riders Debbie and William Loring rode as part of the Saco General Dynamics team. Debbie said she and her husband enjoy bike riding in general, and were riding the 5K course because it was William’s first time participating.
“Next year, we’re doing the next step up” in regards to course length, Debbie said, while William commented that “She’s going easy on me.”
“There’s a lot of people at work who have diabetes, and I see some of what they go through,” Debbie said.
“It’s a great cause,” William said.
Company-sponsored teams are common for Tour de Cure. Belden highlighted Sun Life Financial as a major player, as it’s raised more than $29,000.
“This year, we have Sun Life Financial as our presenting sponsor, and this is their first year coming on,” said Belden. “They have a team of over 100 people, so they really came together, and they have a huge team, a bunch of riders out on the route.”
Club teams also had lots of participants.
“We also have our other large team, which is Philbrick’s Ride. They are a club team, and they are supported by Philbrick’s Bike Shop,” Belden said. “They are, again, almost over 100 riders, and they have raised, I think, almost $40,000 just themselves as a team.”
Other than the teams, there are two other group designations: Red Rider and Champion. A Red Rider is a participant who has diabetes, and a Champion is an individual who has raised more than $1,000 for the cause.
All riders are asked to shout, “Go, Red Rider!” every time they see a person in the Red Rider jersey.
“Everyone that has those Red Rider jerseys are the people that are living with diabetes every day,” said Belden. “This is really for them.”
The 2016 Kennebunk Tour de Cure raised a total of $320,889.48 at the last count, just a little shy of the $400,000 goal. Belden has high hopes for next year’s ride, and said the planning for it “starts tomorrow.”
Comments are not available on this story. Read more about why we allow commenting on some stories and not on others.
We believe it's important to offer commenting on certain stories as a benefit to our readers. At its best, our comments sections can be a productive platform for readers to engage with our journalism, offer thoughts on coverage and issues, and drive conversation in a respectful, solutions-based way. It's a form of open discourse that can be useful to our community, public officials, journalists and others.
We do not enable comments on everything — exceptions include most crime stories, and coverage involving personal tragedy or sensitive issues that invite personal attacks instead of thoughtful discussion.
You can read more here about our commenting policy and terms of use. More information is also found on our FAQs.
Show less